U.S. markets open in 4 hours 3 minutes
  • S&P Futures

    3,809.75
    -29.25 (-0.76%)
     
  • Dow Futures

    31,383.00
    -82.00 (-0.26%)
     
  • Nasdaq Futures

    12,432.25
    -231.50 (-1.83%)
     
  • Russell 2000 Futures

    2,173.60
    -16.10 (-0.74%)
     
  • Crude Oil

    65.88
    -0.21 (-0.32%)
     
  • Gold

    1,688.10
    -10.40 (-0.61%)
     
  • Silver

    25.30
    +0.01 (+0.03%)
     
  • EUR/USD

    1.1874
    -0.0051 (-0.43%)
     
  • 10-Yr Bond

    1.5540
    0.0000 (0.00%)
     
  • Vix

    27.51
    -1.06 (-3.71%)
     
  • GBP/USD

    1.3823
    -0.0005 (-0.04%)
     
  • USD/JPY

    108.5600
    +0.1780 (+0.16%)
     
  • BTC-USD

    49,991.12
    -703.48 (-1.39%)
     
  • CMC Crypto 200

    1,012.17
    +69.00 (+7.32%)
     
  • FTSE 100

    6,621.82
    -8.70 (-0.13%)
     
  • Nikkei 225

    28,743.25
    -121.07 (-0.42%)
     

How Many Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Do Institutions Own?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

Every investor in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. We also tend to see lower insider ownership in companies that were previously publicly owned.

Arcutis Biotherapeutics isn't enormous, but it's not particularly small either. It has a market capitalization of US$1.7b, which means it would generally expect to see some institutions on the share registry. In the chart below, we can see that institutions are noticeable on the share registry. We can zoom in on the different ownership groups, to learn more about Arcutis Biotherapeutics.

View our latest analysis for Arcutis Biotherapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Arcutis Biotherapeutics?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

Arcutis Biotherapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Arcutis Biotherapeutics' historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

Arcutis Biotherapeutics is not owned by hedge funds. Our data shows that Frazier Healthcare Partners is the largest shareholder with 21% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 12% and 12%, of the shares outstanding, respectively. In addition, we found that Todd Watanabe, the CEO has 1.5% of the shares allocated to their name.

Our research also brought to light the fact that roughly 54% of the company is controlled by the top 4 shareholders suggesting that these owners wield significant influence on the business.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Arcutis Biotherapeutics

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own some shares in Arcutis Biotherapeutics, Inc.. The insiders have a meaningful stake worth US$84m. Most would see this as a real positive. It is good to see this level of investment by insiders. You can check here to see if those insiders have been buying recently.

General Public Ownership

With a 18% ownership, the general public have some degree of sway over Arcutis Biotherapeutics. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Equity Ownership

With an ownership of 42%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. For instance, we've identified 3 warning signs for Arcutis Biotherapeutics that you should be aware of.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.